Pitsanu Kraichana / Shutterstock.com
China, Japan and South Korea are three of the most developed markets in the world for pharmaceuticals but they still offer a wealth of opportunities for both innovators and generic drug companies. LSIPR looks at the protection available for those seeking to do business there.
Forecast by information solutions provider IMS Health to be the second, third, and 14th biggest spenders, respectively, in medicine by 2017, and with a combined population of more than 1.5 billion people, China, Japan and South Korea are becoming key markets for the big pharma and biotech companies.
However, as LSIPR found, protection for medicines in the three countries varies widely, as quirks in their national patent systems mean each country has its own way of doing things.
China
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
biotech, pharma, World Health Organisation, generic drugs, patents
